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Chronic inflammation is a hallmark of atheroscle-
rosis, but its transcriptional underpinnings are poorly
understood. We show that the transcriptional re-
pressor Bcl6 is an anti-inflammatory regulator whose
loss in bone marrow of Ldlr/mice results in severe
atherosclerosis andxanthomatous tendonitis, a virtu-
ally pathognomonic complication in patients with
familial hypercholesterolemia. Disruption of the in-
teraction between Bcl6 and SMRT or NCoR with
a peptide inhibitor in vitro recapitulated atherogenic
gene changes in mice transplanted with Bcl6-
deficient bone marrow, pointing to these cofactors
as key mediators of Bcl6 inflammatory suppression.
Using ChIP-seq, we reveal the SMRT and NCoR
corepressor cistromes, each consisting of over
30,000 binding sites with a nearly 50% overlap. While
the complete cistromes identify a diversity of sig-
naling pathways, the Bcl6-bound subcistromes for
each corepressor are highly enriched for NF-kB-
driven inflammatory and tissue remodeling genes.
These results reveal that Bcl6-SMRT/NCoR com-
plexes constrain immune responses and contribute
to the prevention of atherosclerosis.
INTRODUCTION
Atherosclerosis is nowwidely recognized as a chronic inflamma-
tory disease mediated by complex interplay between resident
vascular endothelial, smooth muscle, and infiltrating immune
cells, particularly macrophages (MØs) (Glass and Witztum,
2001). It initiates with the accumulation of lipids in the arterial
intima, which subsequently are modified, triggering endothelial
activation and the recruitment of monocytes/MØs. These engulf554 Cell Metabolism 15, 554–562, April 4, 2012 ª2012 Elsevier Inc.excess lipid to become foam cells, which are hallmarks of
atherosclerosis and principal effectors of chronic inflammation
in the vessel wall.
Rapid transcriptional induction is the mechanistic foundation
for innate immunity, and members of the NF-kB, STAT, AP-1,
EGR, andHIF families arewell-knownmediators ofMØactivation
and atherosclerosis, often driven by Toll-like receptors (TLRs)
and receptors for proinflammatory cytokines (Adhikari et al.,
2006; de Winther et al., 2005). NF-kB has received particular
attention as the prototypic inflammatory regulator, yet studies
to inhibit NF-kB in mice have yielded opposing pro- and antia-
therosclerotic phenotypes in MØs and endothelial cells, respec-
tively (Gareus et al., 2008; Kanters et al., 2003). These results
highlight complexity in dissecting single components of the tran-
scriptional network activating the innate immune response.
To the extent that acute transcriptional induction is a driver
of inflammation, target genes must be tightly regulated because
unrestrained signaling can result in disease. Our attention
focused on B cell lymphoma 6 (BCL6) as a central factor for MØ
quiescence and inflammatory control. BCL6 is a sequence-
specific DNA binding protein that represses transcription via
interactions with various corepressors including SMRT, NCoR,
BCoR, CtBP, NuRD, SIN3A, ETO, and HDACs (Basso and
Dalla-Favera, 2010). The individual contributions of these to
Bcl6 repression are poorly understood. Interestingly, although
known to control B cell development and transformation in
non-Hodgkin’s lymphomas, we have shown that Bcl6 acts
through a dynamic cistrome to inhibit TLR-initiated inflammatory
responses in macrophages via proximate binding to NF-kB
response elements (Barish et al., 2010), and others have docu-
mented Bcl6 repression of cytokines and chemokines (Takeda
et al., 2003; Toney et al., 2000; Yu et al., 2005). Moreover, in
a hypertensive and accelerated vascular disease model, we
found that angiotensin II infusion suppressed Bcl6 expression
in the aorta (Takata et al., 2008). These findings led us to specif-
ically consider Bcl6 as a candidate repressor of atherosclerosis.
Here, we identify a key role for Bcl6 as a pleiotropic inhibitor
of immune and tissue remodeling responses that underlie
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marrow Bcl6, a broad array of atherogenic genes are activated,
resulting in highly aggressive atherosclerosis and xanthomatous
tendonitis, a comorbidity virtually pathognomonic for humans
with familial hypercholesterolemia. Cofactor inhibitor and cis-
trome analyses reveal SMRT and NCoR as critical MØ Bcl6
corepressors concentrated along NF-kB-regulated inflamma-
tory and tissue remodeling genes. Overall, our data describe
a previously unrecognized program through which Bcl6 recruit-
ment of SMRT and NCoR suppresses an inflammatory enhancer
network to limit atherogenic gene induction and thus attenuate
atherosclerosis.
RESULTS AND DISCUSSION
Loss of Bone Marrow Bcl6 Results in Severe
Cholesterol-Dependent Atherosclerosis and
Xanthomatous Tendonitis
To examine the impact of Bcl6 on atherogenesis, we found that,
in contrast to whole-body knockouts, mice transplanted with
Bcl6 null bone marrow show long-term viability (see Figures
S1A and S1B online) (Dent et al., 1997; Ye et al., 1997), leading
us to reconstitute g-irradiated Ldlr/ mice with Bcl6/ (BMT-
KO) or wild-type (BMT-WT) marrow. Multiple cohorts were then
exposed to atherogenic diet for up to 16 weeks. First, we
analyzed the development of lesions after 8weeks.While athero-
sclerosis was minimal in BMT-WT aortas, BMT-KOmice already
had plaques along branchpoints for intercostal arteries and
3-fold more disease (Figure S1C and Figure 1A). Similarly, aortic
root cross-sections demonstrated a nearly 3-fold increase in
lesion area in BMT-KO mice compared to controls (Figure 1B).
Remarkably, assessment of aortic root sections with Masson
trichrome staining and immunostaining revealedmassive lesions
in BMT-KO mice compared to controls, marked by striking
erosions, MØ infiltration, and smooth muscle cells (Figure 1C).
Next, we extended our analysis to mice fed atherogenic diet
for an additional 5 or 8 weeks, and BMT-KO aortas revealed
dramatically more severe atherosclerosis (Figure 1D). Overall,
BMT-KO mice developed up to 5-fold more aortic lesion cover-
age than BMT-WT control mice after 13 or 16 weeks of athero-
genic diet feeding and a 1.6-fold increase in aortic root lesion
area at 16 weeks (Figures 1A and 1B). The modest increase
in root lesions compared to entire aortas suggests that BMT-
KO aortic root lesions were already near maximal by 8 weeks
(Figures 1B and 1C). Consistent with their severe disease, aortic
roots in BMT-KO mice at later time points revealed noticeably
increased lesion complexity, including extensive connective
tissue deposition (Figure 1E) and significantly larger necrotic
cores, resembling advanced human atherosclerosis (Figures
1F and 1G).
Strikingly, BMT-KO mice also displayed disturbed movement
due to abnormal distal limbs and paws (Figure 1H) that were
nearly 38% larger by volume than those of BMT-WT mice after
12 weeks of exposure to atherogenic diet (Figure 1I). Histological
examination revealed xanthomatous tendonitis with surrounding
fibrosis (Figures 1J and 1K and Figures S1D–S1F) and MOMA-
2-positive MØ infiltrates (Figure S1G). Interestingly, evidence
for tendon xanthomas in BMT-KO mice was even apparent by
8 weeks of exposure to atherogenic diet (Figure S1H). ThoughCrarely seen in mice, this pathology is common in LDLR-deficient
patients (familial hypercholesterolemia) and predictive of in-
creased cardiovascular risk (Civeira et al., 2005; Goldstein
et al., 2001; Ishibashi et al., 1994). Together, these findings not
only demonstrate a critical role for Bcl6 to suppress early
vascular lesion development but also atherosclerotic remodeling
and tendon xanthoma.
In similar experiments, we performed transplantation of WT or
KO bone marrow into wild-type C57 mice (C57 BMT-WT and
C57 BMT-KO mice). Remarkably, C57 BMT-KO mice on either
standard diet for 30 weeks (Figures S2A–S2G) or atherogenic
diet for 14 weeks (Figures S2J–S2R) developed no change
in body weight or lipid profile, tendon pathology, or vascular
lesions. These results suggest that hypercholesterolemia is
critical to elicit BMT-KO-related pathology. Importantly, how-
ever, total cholesterol and triglyceride levels, as well as lipopro-
tein fractions, were similar between BMT-WT and BMT-KOmice
(Ldlr/ recipients) on standard or atherogenic diets (Figures
S1I–S1K). Although overall food consumption did not differ,
body weights often diverged after 8 weeks of dietary challenge
and were lower in some BMT-KO cohorts by 13–16 weeks
(Figures S1I and S1L). Correspondingly, inguinal white adipose
tissue, liver, and total body fat were reduced in some of these
groups at 13 or 16 weeks (Figures S1I and S1M). Overall, these
findings indicate a subtle contribution of bone marrow Bcl6 to
metabolic homeostasis in Ldlr/ mice, with weight loss coinci-
dent to severe atherosclerosis and tendon xanthoma in BMT-KO
animals exposed to more than 3 months of atherogenic diet.
Bcl6 Deletion Derepresses Atherogenic Genes and
Sensitizes Macrophages to Oxidized LDL Stimulation
MØs play a central role in atherogenesis, from early fatty streaks
to advanced lesions. Previously, we performed genome-
wide transcriptome analysis for Bcl6 in WT and KO MØs (Barish
et al., 2010). Further evaluation of this data set revealed not only
a collection of Bcl6-repressed chemokines and cytokines but
mitogens, proteases, and clotting factors that collectively pro-
mote leukocyte recruitment, activation and proliferation, plaque
remodeling, and thrombosis. To confirm the microarray findings
and explore the impact of atherogenic stimuli on Bcl6-regulated
genes, we used quantitative PCR (qPCR) to assess mRNA levels
in Bcl6 wild-type (WT), heterozygous (HET), and knockout (KO)
cells with or without exposure tommLDL (Figure 2A, Figure S3A).
In unstimulated MØs, critical chemokines implicated in athero-
sclerosis were substantially derepressed in KO cells including
Ccl2, Ccl7, and Cxcl1 (Zernecke and Weber, 2010). Moreover,
even haploinsufficiency of Bcl6 is sufficient to create a sensitized,
proinflammatory state as maximal or near-maximal expression
changes were seen following exposure of KO and HET cells to
mmLDL and correlated closely to Ccl2 and Ccl7 protein levels
(Figure 2A, Figures S3A–S3B). Csf1 is a pleiotropic MØ growth
factor as well as chemoattractant and thus functions as a power-
ful proatherogenic mediator (Glass and Witztum, 2001). Csf1
levels were fully increased by 30-fold in KO MØs and not further
enhanced by mmLDL (Figure S3A). Notably, WT and KO MØs
were comparable in their ability to migrate to a Ccl2 or Ccl3
chemoattractant gradient in vitro (Figure S3C). Yet in a model
of sterile peritonitis, transplanted mice devoid of bone marrow
Bcl6 generated 2-fold higher leukocyte counts in peritonealell Metabolism 15, 554–562, April 4, 2012 ª2012 Elsevier Inc. 555
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Figure 1. Bcl6 Represses Atherogenesis and Xanthomatous Tendonitis
(A and B) Quantification of en face aorta and aortic root lesions in BMT mice exposed to atherogenic diet.
(C) Aortic valve sections from BMT mice fed atherogenic diet for 8 weeks, showing (top) Masson trichrome staining (connective tissue is blue), (middle)
MØ-specific Moma-2 antibody immunostaining (red), and (bottom) a-smooth muscle actin (SMA) antibody immunostaining (red).
(D) Sudan IV-stained aortas of BMT mice (13 weeks).
(E) Masson’s trichrome staining of aortic root atheromas (*).
(F) Moma-2 immunohistochemical staining (red) with hematoxylin counterstain of aortic root atheromas. Open arrow marks necrotic core in BMT-KO atheroma.
(G) Quantitation of necrotic cores from aortic root lesions in BMT mice after 16 weeks of atherogenic diet, expressed as percentage of total lesion area.
(H) Hindlimbs from BMT-WT and BMT-KO mice. Red arrows indicate lesions.
(I) Quantification of distal hindlimb volumes (n = 10 for BMT-WT, n = 7 for BMT-KO).
(J) Representative sagittal sections comparing BMT-WT and BMT-KO hindlimbs, H&E staining. Section of BMT-KO mouse shows obliteration of the sub-
cutaneous and tendinous tissues with thick fibroblastic proliferation containing cholesterol clefts and mixed inflammatory infiltrate (solid arrows).
(K) High-power view of xanthoma in a BMT-KO mouse showing a collection of foam cell MØs (open arrow) surrounded by fibrosis and inflammatory cells (solid
arrow) and effacement of normal subcutaneous and tendinous tissues (*), H&E staining. For (A), (B), (G), and (I), values are means ±SD. Statistical significancewas
determined using two-tailed t tests: +p < 0.05, #p < 0.01, *p < 0.001.
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Figure 2. Bcl6 Regulates Proatherogenic Genes In Vitro and In Vivo
(A) qPCR assessment of gene expression in WT, HET, and KO MØs ± exposure to mmLDL.
(B) Expression analysis of flushed bone marrow from BMT-WT (n = 6) and BMT-KO (n = 7) mice after 2 weeks of atherogenic diet.
(C) Gene expression in whole aortas from BMT-WT (n = 6) and BMT-KO (n = 7) mice after 2 weeks of atherogenic diet normalized to the F4/80 MØ marker gene.
(D) Plasma protein levels of chemokines in BMT-WT and BMT-KO mice following 13 weeks of atherogenic diet (n = 9 for each cohort).
(E) Representative immunostained aortic root sections from BMT-WT and BMT-KO detecting Ccl2, Il-1a, Plau, and F3 (red) in atherosclerotic lesions following
8 weeks of atherogenic diet. Boxes indicate representative lesions. For (A)–(D), values are expressed asmeans ±SD. Statistical testing to compare the genotypes
for each treatment condition performedwith (A) one-way ANOVA and Tukey’smultiple comparison tests or (B–D) two-tailed t tests: +p < 0.05, #p < 0.01, *p < 0.001.
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tractants from KO inflammatory cells (Figure S3D). Together,
these results suggest that Bcl6 is a core regulatory component
whose loss promotes disease, in part, by derepressing a chemo-
tactic network.
In addition to inflammatory factors, key plaque remodeling
and thrombosis genes were identified as Bcl6 targets. Platelet-
derived growth factors (PDGFs) are potent smooth muscle
mitogens that accelerate vascular stenosis (Andrae et al.,
2008). Notably, Pdgfa was upregulated 3-fold in KO MØs either
in the presence or absence of mmLDL stimulation (Figure 2A).
Tissue remodelingmatrixmetalloproteinases (MMPs) destabilize
atherosclerotic plaques and initiate thrombus formation, and
human genetic studies link variants of MMP12 and MMP13 toCvascular disease (Ye, 2006).Mmp12 andMmp13 were strikingly
(10- and 17-fold, respectively) derepressed in Bcl6 KOMØs, and
in particular, Mmp13 was further stimulated to levels nearly
40-fold over unstimulated WT cells by mmLDL (Figure 2A). Addi-
tionally, the urokinase plasminogen activator (Plau) is expressed
in arterial wall MØs and, when overexpressed, causes acceler-
ated atherosclerosis, vascular occlusion, and plaque rupture
(Cozen et al., 2004). Remarkably, Plau transcripts and protein
were strongly upregulated in Bcl6-deficient MØs (Figure 2A, Fig-
ure S3E), and its mRNA expression further increased bymmLDL.
The lysosomal proteases cathepsin E (Ctse) and cathepsin L
(Ctsl), which is associated with necrotic core formation and
plaque destabilization (Li et al., 2009), were also moderately
upregulated in KO cells (Figure S3A). Finally, tissue factor (F3),ell Metabolism 15, 554–562, April 4, 2012 ª2012 Elsevier Inc. 557
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20-fold higher in KO compared to WT cells. Additional exposure
to mmLDL synergized with Bcl6 deficiency to increase F3 by
60-fold over levels in stimulated control MØs (Figure 2A). Impor-
tantly, loss of Bcl6 also potentiated the effect of other pro-
atherogenic signals, including TLR-2 and TLR-4 ligands, to stim-
ulate the expression of aforementioned chemokines, cytokines,
remodeling enzymes, and clotting factors (Figure S3F and data
not shown). Together, these findings suggest that Bcl6 limits
oxidized LDL- and TLR-induced inflammatory and tissue remod-
eling responses by constraining target gene activation.
Bcl6 Controls Atherogenic Gene Expression In Vivo
To characterize the Bcl6-regulated inflammatory network in vivo,
we initially examined expression profiles in the bone marrow of
transplanted mice. As expected, marrow Bcl6 was virtually
undetectable in Bcl6/ transplant recipients (Figure 2B). Coor-
dinately, Ccl2, Ccl7, Csf1, F3, Mmp12, Mmp13, and Plau were
all significantly increased in atherogenic diet-fed Ldlr/ mice
harboring Bcl6/ marrow compared to controls (Figure 2B).
Similar expression changes were observed in chow- or athero-
genic diet-fed C57Bl/6J transplanted animals (Figures S2H
and S2S). In white adipose tissue, which contains a significant
population of MØs, expression of Ccl7 and Mmp12 was also
relatively elevated in BMT-KO mice (Figure S1N). Moreover,
Bcl6-regulated gene expression was clearly altered in the
aortas of atherogenic diet-fed Ldlr/ transplanted mice, as
levels of Ccl2, Ccl7, Cxcl1, Il-1a, Mmp12, Mmp13, Plau, Ctse,
Ctsl, Pdgfa, and F3 normalized to the MØ marker F4/80
were each significantly up in BMT-KO mice compared to con-
trols (Figure 2C) and resembled expression changes observed
in KO MØs. Some of these differences were even observed in
aortas of C57 BMT-KO mice relative to C57 BMT-WT controls
on standard or atherogenic diets (Figures S2I and S2T). More-
over, Ccl2 and Ccl7 protein were elevated in the plasma of
BMT-KO mice (Figure 2D), and immunohistochemistry demon-
strated increased Ccl2, Il-1a, Plau, and F3 protein within their
aortic valve atherosclerotic lesions (Figure 2E), indicating that
loss of bone marrow Bcl6 can promote vascular and systemic
inflammation.
Since cholesterol metabolism plays a key role in atheroscle-
rosis, we examined vascular expression of several principal
regulators of cellular lipid homeostasis. Importantly, mRNAs of
genes involved in MØ cholesterol uptake (Cd36 and Sra1),
storage (Acat1), and efflux (Abca1, Abcg1, and Apoe) were
similar in BMT-WT and BMT-KO mice (Figure 2C). Interestingly,
examination of MØ cholesterol uptake in vitro revealed a modest
decrease in the ability of KO MØs to internalize oxidized or
acetylated LDL (Figure S3G) and a mild reciprocal defect in their
HDL or ApoA1-mediated cholesterol efflux (Figure S3H). These
differences appear minor and compensated, as levels of total
and esterified cholesterol were similar both in WT and KO
foam cells derived in vitro upon 24 hr exposure to acetylated
LDL (Figure S3I), and in peritoneal MØs from atherogenic diet-
fed BMT-WT and BMT-KO mice (Figure S3J). The minimal
impact of Bcl6 on foam cell cholesterol homeostasis (Figures
S3G–S3J) and circulating lipids (Figures S1I–S1K) supports, by
exclusion, the key role for inflammation to contribute to the
severe atherosclerosis and tendon xanthomas in BMT-KO mice.558 Cell Metabolism 15, 554–562, April 4, 2012 ª2012 Elsevier Inc.Bcl6 Recruits SMRT and NCoR to Repress Atherogenic
Inflammation
Although we recently described the Bcl6 cistrome (Barish et al.,
2010), the molecular composition of cofactors on these thou-
sands of binding sites remained unknown. In light of reports
suggesting roles for SMRT and NCoR in macrophage inflam-
matory control (Ghisletti et al., 2009; Ogawa et al., 2004),
we wondered whether these corepressors contributed to Bcl6
anti-inflammatory repression. Previous work described the
development of a potent, modified therapeutic peptide from
the core of SMRT’s BCL6 interaction domain (termed RI-BPI)
that activates BCL6 target genes by specifically blocking inter-
action between BCL6 and the corepressors NCoR or SMRT to
kill lymphoma cells (Cerchietti et al., 2009). Addition of RI-BPI
to bone marrow-derived MØs resulted in rapid, and in many
cases dramatic, induction of proatherogenic gene transcripts
including Ccl2, Ccl3, Ccl7, Csf1, Cxcl1, Cxcl2, F3, Il-1a, Il-6,
Mmp-13, Pdgfa, and Plau compared to a similar cell-penetrating
control peptide (CP) lacking the BCL6 binding domain (Fig-
ure 3A). Highly similar expression changes were also observed
in primary human bone marrow-derived MØs exposed to RI-BPI
(Figure 3B), indicating that BCL6 controls a conserved inflamma-
tory network. To better understand the contribution of SMRT and
NCoR to Bcl6 repression, we performed genome-wide microar-
ray analysis of mouse MØs exposed for 12 hr to RI-BPI versus
a CP, which identified more than 4000 differentially expressed
transcripts. Notably, RI-BPI treatment recapitulated 35% (892/
2579 transcripts) of the expression changes incurred by genetic
loss of Bcl6 (Barish et al., 2010). Furthermore, functional
classification of RI-BPI-regulated transcripts revealed significant
enrichment for TLR, cytokine-cytokine receptor interaction, and
inflammatory cell signal transduction pathways (Table 1). Col-
lectively, these findings indicated that the atherosclerotic
phenotype of BMT-KO mice involves loss of Bcl6-dependent
NCoR and/or SMRT repression, and conversely, proinflamma-
tory changes observed in NCoR or SMRT-deficient MØs could
in part be attributable to derepression of Bcl6.
Next, we sought to determine the individual contributions of
SMRT and NCoR to the suppression of Bcl6 target genes.
Notably, SMRT and NCoR are highly homologous, and, because
they interact with many transcription factors, their specificity has
previously been difficult to define. ChIP qPCR revealed that both
SMRT andNCoR localized to Bcl6 binding sites along proathero-
genic genes but were reduced along Ccl2, Csf1, Il-1a, and
Mmp12 in MØs lacking Bcl6 (Figure S4A). Then, we performed
ChIP sequencing to uncover the SMRT and NCoR cistromes.
Using a false discovery rate of <0.01, we identified 32,435 and
33,522 binding sites for SMRT and NCoR, respectively, in WT
MØs (Figure 3C). Overall, the SMRT and NCoR cistromes
overlapped at 14,480 binding sites, reflecting at least 45%
redundancy in their genomic localizations (Figure 3C). Motif
analysis (Figure 3D) revealed putative binding sites for the MØ
lineage-determining factors Pu.1, Jun, and C/EBP, which mark
MØ enhancers (Ghisletti et al., 2010; Heinz et al., 2010), as three
of the most common consensus sequences near SMRT and
NCoR binding peaks. Accordingly, the vast majority (R90%) of
SMRT or NCoR binding was promoter distal in distribution,
although NCoR was almost twice as concentrated on promoters
(Figures S4B and S4C). Other top-scoring motifs included those
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Figure 3. Bcl6 Represses Atherogenic Genes Using SMRT and NCoR
(A and B) Gene expression in wild-typemouse (A) and human (B) MØs following 12 hr treatment with 5 mMof control (CP) or Bcl6 inhibitor peptide (RI-BPI). Values
are expressed as means ±SD.
(C) Venn diagram comparing the SMRT and NCoR cistromes and their overlap in wild-typemouseMØs. The numbers of unique and overlapping binding sites are
listed.
(D) Binding site motif predictions based on ChIP-seq of SMRT (left) and NCoR (right) in MØs. The p values were determined by Fisher’s exact test.
(E) Venn diagram comparing the Bcl6-SMRT versus Bcl6-NCoR subcistromes. The numbers of unique and overlapping binding sites are listed.
(F) Motif analysis for the Bcl6-SMRT (top) and Bcl6-NCoR (bottom) cistromes. The p values were determined by Fisher’s exact test.
(G) Graph of the percentage colocalization between the NF-kB cistrome and the Bcl6 cistrome (all sites), SMRT cistrome (all sites), NCoR cistrome (all sites),
Bcl6-SMRT subcistrome, or Bcl6-NCoR subcistrome.
(H and I) ChIP-sequencing tracks for SMRT (blue), NCoR (red), and Bcl6 (black) in wild-type and Bcl6 KO MØs along (H) Ccl2/Ccl7 gene cluster and (I) Plau.
Colocalization of Bcl6, SMRT, and NCoR is observed at several sites in wild-type MØs and is associated with loss of SMRT and NCoR peaks in KO cells. Exon
positions are depicted horizontally in blue. Tag counts are indicated on the vertical axis. Tracks were normalized to 1E+07 reads.
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Runx1 and the nuclear receptor RXR, respectively (Figure 3D).
Next, we determined cistrome subsets for SMRT and NCoR
that were directly attributable to interactions with Bcl6, using
two criteria (Figure S4D). First, we ChIP sequenced SMRT and
NCoR in Bcl6 KO MØs to normalize the sequencing data
obtained in WT cells, thereby identifying SMRT and NCoR sites
that were genetically dependent upon Bcl6. Surprisingly, nearly
half of SMRT and NCoR binding sites were reduced or lost inCBcl6 KO cells, indicating that loss of Bcl6 may directly or indi-
rectly result in widespread genomic derepression. Second, we
analyzed for direct DNA sites of interaction between Bcl6 and
SMRT or NCoR based on colocalization. Previously, we gener-
ated the Bcl6 cistrome in MØs by aligning Bcl6 ChIP-seq reads
to the mouse genome using the Eland alignment tool (Barish
et al., 2010). More recently, we found the Bowtie aligner to be
more efficient, improving ChIP-seq peak calling. Reanalysis of
Bcl6 ChIP-seq reads using Bowtie and otherwise unchangedell Metabolism 15, 554–562, April 4, 2012 ª2012 Elsevier Inc. 559
Table 1. Bcl6-SMRT/NCoR Complexes Control Inflammatory Genes
KEGG Functional Category
(Gene Number in Term)
RI-BPI Regulated
Bcl6-SMRT or Bcl6-
NCoR Bcl6-SMRT Bcl6-NCoR
Bcl6-SMRT and
Bcl6-NCoR
Gene
Number P Value
Gene
Number P Value
Gene
Number P Value
Gene
Number P Value
Gene
Number P Value
Toll-like Receptor Signaling
Pathway (100)
45 6 3 1017 49 1 3 1014 43 5 3 1013 45 3 3 1015 38 7 3 1014
Cytokine-Cytokine Receptor
Interaction (246)
52 2 3 106 86 1 3 1013 78 8 3 1014 64 2 3 108 55 7 3 109
Jak-STAT Signaling Pathway
(153)
44 3 3 109 56 4 3 1010 47 3 3 108 47 6 3 109 38 9 3 108
B Cell Receptor Signaling
Pathway (64)
39 2 3 1017 28 1 3 107 25 4 3 107 27 7 3 109 22 1 3 107
MAPK Signaling Pathway
(258)
79 2 3 1016 73 3 3 107 65 3 3 107 59 7 3 106 47 4 3 105
Natural Killer Cell-Mediated
Cytotoxicity (121)
42 1 3 1011 41 1 3 106 38 3 3 107 36 9 3 107 29 7 3 106
T Cell Receptor Signaling
Pathway (93)
42 3 3 1013 33 4 3 106 29 1 3 105 30 1 3 106 25 3 3 106
Fc Epsilon RI Signaling
Pathway (76)
25 9 3 107 29 3 3 106 24 5 3 105 27 5 3 107 19 2 3 103
Apoptosis (84) 32 4 3 1010 34 7 3 108 27 1 3 105 29 4 3 107 22 2 3 105
Functional analysis of gene expression changes in MØs exposed to RI-BPI peptide (5 mM) for 12 hr and genes annotated with Bcl6-SMRT and/or Bcl6-
NCoR in MØs based on ChIP-seq. Top-scoring KEGG categories were selectively represented. The number of genes in each category is listed.
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binding sites in quiescent MØs (from 6,655 to 14,756 sites).
ChIP qPCR of randomly selected, additional Bcl6 binding peaks
identified from this reanalysis confirmed 90% of these sites (Fig-
ure S4E). Using Bowtie alignments to generate each cistrome
and 200 DNA base pair colocalization windows, we identified
3,665 Bcl6-SMRT and 3,664 Bcl6-NCoR complexes across the
genome. Remarkably, almost 70% of Bcl6-SMRT and Bcl6-
NCoR sites were shared by both corepressors (Figure 3E), and
motif analysis of these subcistromes produced the same top-
scoring sequences for Pu.1 and Bcl6 (Figure 3F). These results
reflect a high degree of overlap between SMRT and NCoR in
the repression of Bcl6, which together control one-third of the
Bcl6 cistrome (4,795/14,756 Bcl6 binding sites).
Importantly, additional analysis of the Bcl6-SMRT and Bcl6-
NCoR subcistromes revealed dramatic enrichment for proin-
flammatory, atherogenic genes and pathways. Classification of
Bcl6-SMRT and/or Bcl6-NCoR annotated genes identified
TLR, cytokine-cytokine receptor interaction, and inflammatory
cell signaling transduction pathways as the most highly enriched
functional groups, highly reminiscent of our functional analysis
for RI-BPI-regulated gene expression (Table 1). In fact, among
genes annotated with one or more Bcl6-SMRT/NCoR binding
sites, the expression of 87% (2,677/3,076) was impacted by
RI-BPI, and 63% of genes whose expression was altered by
12 hr exposure to RI-BPI were directly bound by Bcl6-SMRT
and/or Bcl6-NCoR complexes. Moreover, although <20% of
genes annotated with Bcl6 binding sites demonstrate corre-
sponding changes of expression in Bcl6 KO MØs (Barish et al.,
2010; and data not shown), the majority (720/1,279) of such tran-
scriptionally altered, direct target genes contain Bcl6-SMRT/
NCoR binding sites. These results suggest that SMRT and
NCoR are markers for transcriptionally relevant Bcl6 binding560 Cell Metabolism 15, 554–562, April 4, 2012 ª2012 Elsevier Inc.sites, and the Bcl6-SMRT/NCoR subcistromes may have domi-
nant functional roles to impact the MØ Bcl6 regulatory program.
Direct examination of sequencing tracks along key Bcl6-
repressed atherogenic genes such as Ccl2/Ccl7 and Plau illus-
trated strong Bcl6-associated recruitment of SMRT and NCoR
(Figures 3H and 3I). Even SMRT and NCoR peaks that did not
colocalize with Bcl6 were in some instances lost in KO cells,
presumably due to secondary impacts of Bcl6 derepression
(Figures 3H and 3I). At other genomic loci not regulated by
Bcl6, such as Slain2, SMRT and NCoR binding was similar in
WT and KO cells (Figure S4F). Furthermore, although SMRT
and NCoR binding peaks were highly overlapping, recruitment
to some sites was corepressor specific, such as NCoR recruit-
ment to the Nos2 (iNos) promoter, consistent with other reports
(Ghisletti et al., 2009) (Figure S4G). Previously, we found that
Bcl6 and NF-kB antagonize the expression of thousands of
genes by proximately binding enhancers (Barish et al., 2010).
Given the strong enrichment for Bcl6-SMRT and Bcl6-NCoR at
inflammatory genes, we wondered to what extent these sub-
cistromes oppose NF-kB. Using our previously described
NF-kB cistrome of over 31,000 binding sites in MØs, we found
that the Bcl6, SMRT, and NCoR cistromes demonstrate sub-
stantial proximal overlap with NF-kB, corresponding to 22%,
30%, and 40% of their respective binding sites (Figure 3G).
Remarkably, however, the Bcl6-SMRT and Bcl6-NCoR sub-
cistromes were still further enriched for proximally bound
NF-kB, corresponding to nearly 60% of these sites (Figure 3G).
Together, these findings define a particular role for Bcl6-SMRT
andBcl6-NCoR complexes in opposing NF-kB-driven inflamma-
tory and tissue remodeling genes, which are derepressed in
highly atherosclerosis-prone Bcl6 KO-BMT animals.
While robust acute inflammatory responses are critical
for survival, unchecked inflammation underlies a broad array of
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Bcl6-SMRT/NCoR Cistrome Suppresses Atherosclerosispathologies, including atherosclerosis. Here, we identify a critical
role for Bcl6 to suppress oxidized LDL- and TLR-induced inflam-
mation and atherogenesis. Accordingly, loss of transcriptional
repression in Bcl6-deficient bone marrow produces among the
most aggressive atherosclerosis reported in a Ldlr/ bone
marrow transplantation model, along with xanthomatous
tendonitis, a complication rarely seen in mice but virtually patho-
gnomonic for familial hypercholesterolemia. Although additional
studies will be needed to fully dissect the Bcl6 repression
network, our expression and genomic analyses identify SMRT
and NCoR as major components in Bcl6 opposition to athero-
genic and NF-kB-driven inflammation. The pathological conse-
quences of losing Bcl6 repression raise questions about the
basis of chronic inflammatory disease and its treatment. Do
such maladies occur through the aberrant signaling of activation
pathways such as NF-kB, or could loss of repression play an
equal or alternate role? Moreover, could enforcement of Bcl6
repression be leveraged therapeutically? Future investigations
of Bcl6 or other repression pathways controlled by SMRT and
NCoR may offer insight into these questions.
EXPERIMENTAL PROCEDURES
Animal Experiments
Ldlr/ or C57Bl/6Jmalemicewere obtained from The Jackson Laboratory. All
procedures were approved by the Salk Institute or University of California,
Los Angeles Animal Research Committees. For transplantation, mice were
irradiated with 1000 rads, injected retro-orbitally with 2 3 106 bone marrow
cells from donor mice, and reconstituted for 4 weeks prior to dietary challenge.
Lesion analysis was performed as described in the Supplemental Information.
Primary MØ Differentiation and Culture
Marrow was flushed from the femurs and tibias of male C57Bl/6J animals (The
Jackson Laboratory) or C57Bl/6J mice transplanted and reconstituted with
Bcl-6+/+, Bcl-6+/, or Bcl-6/ bone marrow (to amplify marrow material) and
differentiated in culture media containing L929 cell supernatant, as previously
detailed (Barish et al., 2010). Ligand treatment, cholesterol trafficking, foam
cell formation, and chemotaxis assays were performed as described in the
Supplemental Information.
Gene Expression
RNA extraction, qPCR, and microarray analysis were performed as previously
described (Barish et al., 2010). Expression is graphed as the mean of all repli-
cates (biological and technical), normalized to the 36B4 housekeeping gene
unless otherwise specified, and shown as relative fold with standard deviation.
Chromatin Immunoprecipitation and ChIP Sequencing
Chromatin immunoprecipitation (ChIP) assays were performed as previously
described (Barish et al., 2010) using antibodies to preimmune IgG, BCL6
(Santa Cruz), or nonhomologous regions of mouse SMRT and NCoR. Values
are expressed as percentages of input chromatin DNA. ChIP-seq analysis
was performed using HOMER (http://biowhat.ucsd.edu/homer/).
ACCESSION NUMBERS
Microarray and ChIP-seq data are deposited at the Gene Expression Omnibus
(GEO) under accession number GSE27060.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at doi:10.1016/j.cmet.2012.02.012.CACKNOWLEDGMENTS
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